Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

50.36 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
PTCT Earnings Beat but Sales Drop 4%
Via The Motley Fool
Topics Earnings
PTC THERAPEUTICS INC (NASDAQ:PTCT) Reports Q2 2025 Earnings Beat with Narrowed Loss and Strong Sephience™ Launch
PTC Therapeutics (PTCT) reported strong Q2 2025 earnings, beating revenue estimates at $179M and narrowing EPS loss. Growth driven by Sephience™ launch for PKU in U.S. & Europe. Stock up 5.4% in a... 
Via Chartmill
Topics Earnings
Earnings Scheduled For August 7, 2025
 
Via Benzinga
PTC Therapeutics Earnings Preview
 
Via Benzinga
Sephience Gets FDA Approval, Now A Key Revenue Driver For PTC Therapeutics
PTC Therapeutics secures FDA approval for Sephience in PKU, launching August with analysts projecting strong revenue and broad patient impact. 
Via Benzinga
These Analysts Increase Their Forecasts On PTC Therapeutics
 
Via Benzinga
FDA Approval Sparks Bullish Momentum In PTC Therapeutics — Here’s What Happened
The regulator approved Sephience for a broad range of PKU patients, including children as young as one month, based on Phase 3 data showing sustained reductions in phenylalanine levels. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock at a Fair Valuation
PTC Therapeutics (PTCT) offers strong growth potential with solid financials and attractive valuation, making it a top pick for investors seeking affordable growth in biopharma. 
Via Chartmill
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
PTC THERAPEUTICS INC (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, supported by solid financial health and profitability metrics. A biotech stock worth watching. 
Via Chartmill
PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock with Technical Breakout Potential
PTC THERAPEUTICS INC (NASDAQ:PTCT) shows strong growth fundamentals and a promising technical breakout pattern, making it a stock to watch for growth investors. 
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential at a reasonable valuation, with solid profitability and financial health. A closer look at this biotech stock may be worthwhile for growth... 
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation
PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, solid profitability, and financial health, making it an interesting stock for growth investors. 
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday
 
Via Benzinga
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.